[New Drug Spotlight] Nerandomilast: A First-in-Class Selective PDE4B Inhibitor Targeting Inflammation and Fibrosis in IPF

Nerandomilast is a novel treatment option for adults with idiopathic pulmonary fibrosis (IPF), approved by the U.S. FDA on October 7, 2025.

[Commercial Synthesis Spotlight] Biocatalytic Aerobic Oxidation: A Scalable Route to trans-3-Hydroxy-L-Proline

Trans-3-hydroxy-L-proline is a noncanonical amino acid that plays a vital role in pharmaceutical development.

[New Drug Spotlight] Brensocatib - A First-in-Class DPP1 Inhibitor Targeting Neutrophil-Driven Inflammation in Bronchiectasis

Brensocatib (Brinsupri™) was approved by the U.S. FDA on August 12, 2025, for the treatment of adults and children 12 years of age and older with non-cystic fibrosis bronchiectasis (NCFB).

[Commercial Synthesis Spotlight] Scalable Synthesis of the Key Intermediate of Antibiotic RSC-435830

RSC-435830 (also known as GSK-3342830) is a β-lactam antibiotic featuring a rare C2 (S)-methylcephalosporin motif.

[New Drug Spotlight] Taletrectinib - A Next-Generation ROS1 Inhibitor Targeting Resistant Mutations and Brain Metastases

Taletrectinib (Ibtrozi®; Dovbleron® in China) was approved by China’s NMPA in December 2024 for adult patients with locally advanced or metastatic ROS1-positive NSCLC and received FDA approval on June 11, 2025 for the same indication.

[New Drug Spotlight] Casdatifan - A Second-Generation Oral HIF-2α Inhibitor in Clinical Development for ccRCC

Casdatifan is a second-generation, orally bioavailable HIF-2α inhibitor developed by Arcus Biosciences.

[Commercial Synthesis Spotlight] Kilogram-Scale Synthesis and Impurity Profiling of LY104

LY104 is a novel compound designed as a potential therapeutic for chronic obstructive pulmonary disease (COPD), a severe inflammatory airway condition.

[Commercial Synthesis Spotlight] Scalable Synthesis of the Key Intermediate of Udifitimod (BMS-986166)

Udifitimod (BMS-986166) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) modulator developed for immunological indications such as atopic dermatitis and other autoimmune disorders.